ImmunityBio (IBRX)
NASDAQ:IBRX
Want to see IBRX full AI Analyst Report?
N-803, Anktiva, Nogapendekin Alfa Inbakicept, Sotevtamab, Zabadinostat, Nab Paclitaxel / Gemcitabine
Pancreatic Cancer, Pancreatic Cancer Resectable
Phase I
Not Yet Recruiting
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Nov 20, 2025
―
N-803
Long Covid
Phase II
Recruiting
A Study to Assess Anktiva in Patients With Long Covid-19.
Jul 30, 2025
―
N-803 And Bcg, N-803 And Gemcitabine
Non-Muscle Invasive Bladder Cancer (Nmibc)
Phase II
Not Yet Recruiting
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
Feb 05, 2025
―
Intravesical Recombinant Mycobacterium
Nmibc
Phase I/II
Recruiting
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
Jan 24, 2025
―
N-803, Etbx-071, M-Cenk
High-Risk Prostate Cancer
Phase II
Not Yet Recruiting
Immunotherapy Before and After Surgery
Dec 23, 2024
―
N-803, Etbx-071, M-Cenk, External Beam Radiation Therapy, Androgen Deprivation Therapy, Post-Radiation Immunotherapy
High-Risk Prostate Cancer
Phase II
Not Yet Recruiting
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.
Dec 20, 2024
―
Docetaxel, N-803, Tislelizumab
Nsclc Stage Iv
Phase III
Recruiting
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
Dec 17, 2024
―
Gemcitabine, N-803, M-Cenk
Platinum-Resistant Ovarian Cancer
Phase II
Recruiting
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
Nov 05, 2024
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does ImmunityBio (IBRX) have in its pipeline
IBRX is currently developing the following drugs: N-803, Anktiva, Nogapendekin Alfa Inbakicept, Sotevtamab, Zabadinostat, Nab Paclitaxel / Gemcitabine, Cd19 T-Hank- Iv Administration, N-803. These drug candidates are in various stages of clinical development as the company works toward FDA approval.